Study of a new drug for advanced bladder and other solid tumors
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: bladder cancer, triple-negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer, head and neck cancer, or prostate cancer that has spread or cannot be removed by surgery.
- You should have already tried at least one standard treatment for your cancer (if it has spread). Some groups of the study require this.
- You must be able to do your daily activities with little or no help (ECOG score 0 or 1).
- You need to have a tumor sample (from a past biopsy or a new one) available for testing.
- You cannot have untreated or growing brain metastases, uncontrolled diabetes, high calcium levels, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a new targeted drug (LY4175408) for people with certain advanced solid tumors (lung, endometrial, or triple negative breast cancer) who have already tried standard treatments. The goal is to see if the drug is safe and effective.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
This trial tests a new combination treatment (CVL006 plus other drugs) in people with advanced solid tumors that have stopped responding to standard therapies. It aims to see if the combination can shrink tumors and help patients live longer.
This trial tests a new study drug (GB-4362) when added to the usual combination of enfortumab vedotin and pembrolizumab for advanced bladder cancer. It is for people who are about to start this standard treatment and have not had these drugs before.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
Hear when a new Metastatic Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.